Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Magnus1 who wrote (12705)	4/6/2020 3:36:17 PM
From: Straynut	Respond to of 12871

Well said Magnus! I can't imagine why they would troll the boards of NNVC without owning a share. Doesn't make any sense to me unless to cause discontent.

To: Magnus1 who wrote (12705)	4/6/2020 3:53:06 PM
From: HardToFind	1 Recommendation Recommended By Savant Read Replies (2) \| Respond to of 12871

For sure whatever the motivation, it has become personal. I think you're right that it has become personal. I think it became personal very early on. If you look over why Yidam, Ltd. sued, you'll find that Diwan caused a lot of folks to lose money because of his actions (akin to theft, IMO) at the start of this company and its licensing agreement: An horrendous licensing deal was made after he had collected investors' money, a deal signed only by himself and (I believe) another owner of TheraCour. Then there was the subsequent changing of the original deal to remove VZV and many other types of herpes viruses, and the original somehow was "lost" (yeah...bulls--t). The difficulty for the company to raise money because, under the current deal, Diwan is positioned to take all of the potential profits that could be reasonably expected. Unlike some other detractors, I believe in the science. But the business structure of this enterprise was not laid out in the interest of NNVC common shareholders. I'm sure Diwan can justify in his own mind the fairness of the deal, but that is more a reflection of his low ethical standards than it is the fairness of the deal. A word of advice, if the company's drugs show success and the stock price rises, don't forget to get out before the details of the licensing deal and structure of the company come under greater scrutiny. I took the opportunity to get out on a recent Covid-19 run-up, and I most certainly do not regret it. Getting in in the first place on the strength of the science, without thoroughly vetting management, is what I regret.